Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $932,549.12 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the transaction, the chief executive officer owned 1,125,848 shares in the company, valued at $32,064,151.04. The trade was a 2.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Down 3.1%

Shares of NASDAQ LQDA traded down $0.86 during trading hours on Tuesday, hitting $26.81. The company’s stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. Liquidia Corporation has a 12 month low of $21.94 and a 12 month high of $93.61. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 20.20 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The business has a 50-day simple moving average of $63.40 and a 200-day simple moving average of $61.76.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter last year, the business posted ($0.49) EPS. The company’s quarterly revenue was up 1842.1% compared to the same quarter last year. On average, analysts anticipate that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LQDA. Wedbush set a $58.00 price objective on shares of Liquidia in a research report on Friday, October 2nd. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $30.00 target price (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. Bank of America lifted their target price on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Lifesci Capital cut shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Wednesday, August 12th. Finally, Piper Sandler set a $129.00 price target on shares of Liquidia in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $83.69.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in LQDA. Globeflex Capital L P bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $175,000. Nykredit A S bought a new position in Liquidia during the 2nd quarter valued at approximately $177,000. Hurley Capital LLC increased its position in Liquidia by 140.7% during the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after buying an additional 3,040 shares in the last quarter. Apollon Wealth Management LLC bought a new position in Liquidia during the 1st quarter valued at approximately $247,000. Finally, Archer Investment Corp purchased a new position in Liquidia during the first quarter valued at $259,000. Institutional investors own 64.54% of the company’s stock.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).